| Direct effects of the hypoxic cell sensitizer misonidazole on colony formation in a human tumor cloning assay. | |
| | |
MedLine Citation:
|
PMID: 3955496 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The human tumor cloning assay as described by Hamburger and Salmon was utilized to study the direct antitumor effects of the hypoxic cell sensitizer misonidazole (MISO). Cells from 106 tumor specimens directly obtained from patients were exposed to MISO at clinically achievable drug concentrations (0.5 mM). Of 30 evaluable tumors, seven specimens (23%) showed a less than or equal to 50% decrease of TCFU's. In vitro sensitivity to MISO was noted in human breast cancer, renal cancer, non small-cell lung cancer, and adenocarcinoma of unknown primary site. A dose response relationship was demonstrated in a subset of experiments including 6 patient's tumors and one human breast cancer cell-line. An analysis relating MISO sensitivity or resistance to the results obtained with other, simultaneously tested standard anticancer drugs indicated that tumors exhibiting a less than or equal to 50% decrease of TCFU's in the presence of MISO were also likely to be sensitive to other cytotoxic drugs. In summary, our data suggest that the 'nitroimidazoles' may exert clinically significant direct antitumor effects in individual tumors. The human tumor cloning assay may have potential to evaluate these direct effects of MISO-analogues and other new radiosensitizers currently being tested in clinical trials. |
| | |
Authors:
|
W Scheithauer; D D Von Hoff; B Forseth; J D Cowan |
Related Documents
:
|
11518616 - Towards in-vitro prediction of an in-vivo cytostatic response of human tumor cells with... 21505426 - Combined flt3l/tk gene therapy induces immunological surveillance which mediates an imm... 21222006 - Secretory meningiomas: systematic analysis of epidemiological, clinical, and radiologic... 21533576 - Aggressive large cell medulloblastoma extending to the extracranial region in brain-dea... 8528296 - Malignant peripheral neuroectodermal tumors in urology. 16507116 - Intra-articular injection of recombinant trail induces synovial apoptosis and reduces i... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Cancer drug delivery Volume: 3 ISSN: 0732-9482 ISO Abbreviation: Cancer Drug Deliv Publication Date: 1986 |
Date Detail:
|
Created Date: 1986-05-09 Completed Date: 1986-05-09 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 8409965 Medline TA: Cancer Drug Deliv Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 15-24 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
pharmacology Colony-Forming Units Assay* Dose-Response Relationship, Drug Female Humans Male Misonidazole / pharmacology* Oxygen Tumor Stem Cell Assay* |
| Grant Support | |
ID/Acronym/Agency:
|
CA27733-04/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 13551-87-6/Misonidazole; 7782-44-7/Oxygen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A pilot home-based geriatric health screening project in primary care.
Next Document: 131-I coupled to monoclonal antibodies as therapeutic agents for neuroectodermally derived tumors: f...